Integration of blood Biomarkers

Work package seven: blood biomarker research in DART

DART blood biomarker research explores the value of blood biomarker tests to improve lung health checks and early lung cancer diagnosis.

Results from DART provide a base for cutting edge research into novel liquid biopsy and genomic technologies in early lung cancer diagnosis and screening. Working with Roche Diagnostics and academic partners DART blood biomarker research explores the value of blood biomarker tests to improve lung health checks and early lung cancer diagnosis.

“When cancer is caught sooner, we have a much better chance of being able to treat it successfully, often with less invasive procedures and fewer long-term side effects. This research into blood biomarkers in the DART research program could give us vital information on the early diagnosis of lung cancer and help us reduce the number of biopsies and PET-CT scans performed in lung health checks. This would reduce the need for further invasive tests for patients, reduce costs to the NHS, increase capacity and improve accuracy of diagnosis. In combination with AI biomarkers, the DART trial will reduce the number of scans patients need to find these early stage, potentially curable lung cancers, increasing productivity and the conversion rate of positive screens to reduce patient anxiety and costs.”

Dr Lee, work package lead

Work package 7 (Integration of Blood Biomarkers) is led by Dr Richard Lee, supported by Roche Diagnostics and Optellum.